• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

3D Systems ($DDD) Forms Systemic Bio to Accelerate Drug Discovery and Development

By: TheNewswire.com
September 09, 2022 at 12:15 PM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Green Stock News LLC
 

 

September 9, 2022 – TheNewswire - 3D Systems (DDD) has announced the formation of a new wholly owned company named Systemic Bio. The new biotech company will focus on the application of advanced bio-printing technologies for pharmaceutical drug discovery and development. 

 

The company says that Systemic Bio will leverage its breakthrough production-level bioprinting technology to create extremely precise vascularized organ models using biomaterials and human cells. These proprietary organs-on-chips can be manufactured reproducibly in large quantities and then perfused with desired drug compounds to study drug metabolism and the effects on healthy or diseased tissue at early stages of new pharmaceutical drug development. 

 

The ability to accurately simulate human response to an experimental drug in the laboratory, early in the development process, will offer the potential to significantly reduce both high costs and extended timelines required for pharmaceutical companies to bring new drugs to market. Additionally, the company says that this approach could eventually reduce or even eliminate the need for animal testing as a precursor to full-scale human trials for new drug development.

 

Dr. Jeffrey Graves, President and CEO of 3D Systems stated: “I am pleased and inspired by the progress we continue to make in the emerging field of regenerative medicine. The complexity and precision that we have now demonstrated using biocompatible materials and our most advanced production bioprinting platform technology is truly groundbreaking, opening a host of new applications ranging from the laboratory to replacement organs within the human body.”

 

3D Systems says that it will provide $15 million in seed funding to demonstrate efficacy of the technology and associated business model. The company is targeting revenues for Systemic Bio to approach $100 million annually within five years.


Shares of 3D Systems trade on the NYSE under the ticker symbol DDD. For more information visit www.greenstocknews.com

 

Disclaimer

 

This content is not financial advice and is for information, education and entertainment purposes only. Green Stock News is not responsible for any losses related to the financial decisions made by you. Video content and other materials including web content are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Green Stock News is not responsible for any gains or losses that result from the opinions expressed in this video or materials that it publishes electronically.

 

View original video news clips here: https://greenstocknews.com/green-stock-newswire 

  

Copyright (c) 2022 TheNewswire - All rights reserved.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More
News headline image
Global Ship Lease Q1 Earnings Call Highlights ↗
Today 12:03 EDT
Via MarketBeat
Topics Earnings World Trade
Tickers GSL
News headline image
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer ↗
Today 11:09 EDT
Via MarketBeat
Tickers BCAX
News headline image
Flowers Foods Q1 Earnings Call Highlights ↗
Today 11:09 EDT
Via MarketBeat
Topics Earnings Economy
Tickers FLO
News headline image
Frontline Q1 Earnings Call Highlights ↗
Today 11:09 EDT
Via MarketBeat
Topics Earnings Supply Chain
Tickers FRO
News headline image
Imperial Petroleum Q1 Earnings Call Highlights ↗
Today 11:09 EDT
Via MarketBeat
Topics Earnings
Tickers IMPP

Recent Quotes

View More
Symbol Price Change (%)
AMZN  269.14
+0.68 (0.25%)
AAPL  309.89
+4.90 (1.61%)
AMD  470.24
+20.65 (4.59%)
BAC  51.88
+0.39 (0.76%)
GOOG  383.05
-0.42 (-0.11%)
META  609.18
+1.80 (0.30%)
MSFT  420.32
+1.23 (0.29%)
NVDA  217.22
-2.29 (-1.04%)
ORCL  192.92
+3.15 (1.66%)
TSLA  430.67
+12.82 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap